TriNutra, the supplier of ThymoQuin® premium USP black seed oil, has announced its recent U.S. patent for compositions comprising ThymoQuin and astaxanthin.
The patent protects compositions that combine TriNutra’s standardized ThymoQuin with astaxanthin and other biologically active compounds. According to the patent, these combinations demonstrated synergistic biological activity, supporting enhanced efficacy compared to the individual ingredients alone.
Thymoquinone (TQ) and p-cymene are key bioactive components in Nigella sativa (black seed) oil and are unstable in the presence of oxidants, such as free fatty acids. This leads to reduced potency and diminished stability of black seed oil. It was therefore a major goal of TriNutra to develop technologies that standardize, stabilize, and maintain the natural balance of bioactive compounds within its premium USP black seed oil brands. The natural bioactives work synergistically among themselves, with additional synergistic enhancement when combined with other ingredients.
“Our unique formulation approach continues to demonstrate that the composition of black seed oil’s bioactives matters significantly,” said Morris Zelkha, CEO of TriNutra. “ThymoQuin has brought innovation to this ancient ingredient with several published clinical trials on its health benefits and composition-dependent efficacy, and numerous global patents back it for its composition, stability, bioavailability, and use. We are incredibly proud of yet another achievement for ThymoQuin and its potential in health and wellness.”
ThymoQuin achieves its unique, specific composition balancing thymoquinone, p-cymene, and free fatty acids (FFAs) through its strict growing, harvesting, and proprietary cold-press manufacturing processes. Published clinical research demonstrated that ThymoQuin supports healthy cortisol levels, while also promoting a balanced, eubiotic gut microbiome, better mood and sleep, cardiometabolic support with healthy blood pressure control, a balanced inflammatory response, cellular energy production, and antioxidant protection.
Astaxanthin is known for its potential to support a healthy inflammatory response, cognitive function, cardiovascular health, mood states, and more. TriNutra’s published research, which initiated this patent, demonstrated that the pairing had a synergistic effect, potentiating astaxanthins’ inflammatory activity.
Zelkha continued, “ThymoQuin was specifically developed to preserve and optimize the key bioactives found in black seed oil, and our research found that pairing it with astaxanthin resulted in synergistic biological activity, particularly in supporting a balanced inflammatory response and antioxidant protection.”
The patent award comes on the heels of TriNutra’s continued advancement of quality standards and scientific substantiation for its premium USP black seed oil ingredients, including the publication of the clinical research demonstrating that ThymoQuin® significantly reduced cortisol levels while improving sleep quality and stress resilience in moderately stressed adults. As well as its published clinical research on ThymoQuin®-OCare for oral health, which demonstrated improvements in gingival function, plaque accumulation, oral microbiome diversity, and overall oral wellness.
These achievements further strengthen TriNutra’s growing intellectual property portfolio, which includes patents covering standardized high-thymoquinone black seed oil compositions, enhanced stability, and bioavailability. ThymoQuin is available across dietary supplements, beauty (B’utyQuin), oral health (ThymoQuin-Ocare), and pet health. It is available in powder and oil formats, providing formulation flexibility across tablets, capsules, soft gels, functional foods, creams, lotions, serums, and more. To learn more about ThymoQuin®, visit TriNutra.com or www.ThymoQuin.com.
